These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 23242717)
1. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience. Perri P; Fiorica F; D'Angelo S; Lamberti G; Parmeggiani F; Martini A; Carpenteri F; Colosimo C; Micucci M; Perazzini L; De Gugliemo E; Berretta M; Sebastiani A; Cartei F Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717 [TBL] [Abstract][Full Text] [Related]
2. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063 [TBL] [Abstract][Full Text] [Related]
3. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155 [TBL] [Abstract][Full Text] [Related]
4. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534 [TBL] [Abstract][Full Text] [Related]
5. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications. Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868 [TBL] [Abstract][Full Text] [Related]
7. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839 [TBL] [Abstract][Full Text] [Related]
8. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. Perez BA; Mettu P; Vajzovic L; Rivera D; Alkaissi A; Steffey BA; Cai J; Stinnett S; Dutton JJ; Buckley EG; Halperin E; Marks LB; Mruthyunjaya P; Kirsch DG Int J Radiat Oncol Biol Phys; 2014 May; 89(1):127-36. PubMed ID: 24613808 [TBL] [Abstract][Full Text] [Related]
9. 18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. van Ginderdeuren R; van Limbergen E; Spileers W Br J Ophthalmol; 2005 Oct; 89(10):1306-10. PubMed ID: 16170122 [TBL] [Abstract][Full Text] [Related]
16. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool. Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414 [TBL] [Abstract][Full Text] [Related]
17. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients - the Tuebingen experience. Süsskind D; Dürr C; Paulsen F; Kaulich T; Bartz-Schmidt KU Acta Ophthalmol; 2017 Dec; 95(8):e727-e733. PubMed ID: 27914117 [TBL] [Abstract][Full Text] [Related]
19. Retina dose as a predictor for visual acuity loss in Heilemann G; Fetty L; Blaickner M; Nesvacil N; Zehetmayer M; Georg D; Dunavoelgyi R Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902 [TBL] [Abstract][Full Text] [Related]